Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593023 | 1.00 | ALDH1A1 (0.62) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL1313958 | 0.93 | ALDH1A1 (0.60) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL6976869 | 0.91 | ALDH1A1 (0.69) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL12593016 | 0.91 | ALDH1A1 (0.69) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL510895 | 0.91 | ALDH1A1 (0.69) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL14725009 | 0.86 | ALDH1A1 (0.66) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL339186 | 0.86 | ALDH1A1 (0.66) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL338450 | 0.86 | ALDH1A1 (0.66) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL6976500 | 0.86 | ALDH1A1 (0.64) | ALDH1A1LMNATHRBSMN1; SMN2HIF1A | |
| SCHEMBL6984781 | 0.84 | ALDH1A1 (0.61) | ALDH1A1TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758916-B1 | 3-BETA-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-8211863-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034802-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-7858637-B2 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | AVERETT DEVRON R | 2010-12-28 | — | — | US | disclosed |
| US-20100256169-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7745415-B2 | 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-7745415-B2 | 3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| EP-1667694-B1 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS INC (US) | 2010-04-28 | — | — | EP | disclosed |
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20080255063-A1 | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080070852-A1 | 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof | ANADYS PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-20080070852-A1 | 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof | ANADYS PHARMACEUTICALS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7321033-B2 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321033-B2 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321033-B2 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1667694-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | Anadys Pharmaceuticals, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050070556-A1 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | US | disclosed |
| WO-2005025583-A2 | TLR7 LIGANDS FOR THE TREATMENT OF HEPATITIS C | ANADYS PHARMACEUTICALS, INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | ANADYS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298863-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | ALDH1A1 1015/4885LMNA 2024/4885THRB 1710/4885 |
| US-20080255063-A1 | 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF | DPYD, TYMP, DCTD | ALDH1A1 904/4885LMNA 3476/4885THRB 3742/4885 |
| US-20120028999-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | ALDH1A1 1015/4885LMNA 2024/4885THRB 1710/4885 |
| US-20080070852-A1 | 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof | ADORA2B, DPYD, ADAR | ALDH1A1 1059/4885LMNA 1741/4885THRB 1585/4885 |
| US-20050070556-A1 | 3-B-D-ribofuranosylthiazolo [4,5-d] pyridimine nucleosides and uses thereof | ENTPD5, DPYD, TYMP | ALDH1A1 1278/4885LMNA 1907/4885THRB 3825/4885 |
| US-20100256169-A1 | ADMINISTRATION OF TLR7 LIGANDS AND PRODRUGS THEREOF FOR TREATMENT OF INFECTION BY HEPATITIS C VIRUS | TLR7, TLR3, TLR9 | ALDH1A1 1015/4885LMNA 2024/4885THRB 1710/4885 |
| US-20050054590-A1 | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus | TLR7, TLR3, TLR9 | ALDH1A1 1015/4885LMNA 2024/4885THRB 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.